Canadian medical technology company Orpyx will release its first product, the SurroSense Rx, later this year, reported the company’s CEO and president, Breanne Everett, MD, a resident in the Division of Plastic and Reconstructive Surgery at the University of Calgary.
The SurroSense Rx is a pressure-sensing insole designed to help patients with diabetic peripheral neuropathy detect foot damage. The eight force sensors in the insole collect pressure data from the foot and send it wirelessly to the user through a wristband display or other wireless-enabled device, including tablets or smartphones. The full SurroSense Rx system, which includes two insoles and shoe pods, wireless system, wristwatch, and app, will cost around $900. Users will need to replace insoles every six to 18 months; replacement insoles will cost about $200.
Everett founded Calgary-based Orpyx in 2010. Trials of its second product, the SurroGait Rx, a sensor grid to measure pressure over the bottom of the foot, will begin in early 2013.
